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INTRODUCTION 
  Drug delivery through the oral mucosal membrane is considered as alternative to the oral 
route. The sublingual region of the oral cavity in the floor of the mouth is far more permeable 
than the buccal cavity (Leow et al., 1992).The permeability differences are usually based on the 
comparative thickness, supply of blood and keratinisation of the membranes. Difference in the 
permeability of the various mucous membranes, affects the amount of drug delivery from the 
physicochemical properties to be delivered. The sublingual root (Physiological pH 6.5) has the 
ability for providing a substitute to IV dosing for quick delivery of drugs to the systemic flow. It 
bypasses gastrointestinal and presystemic metabolism and is a suitable form for delivery of drug 
relevant in patients with difficulties in swallowing (Kurosaki et al., 1991). 
Tablet that are disintegrated/dissolved quickly in patient’s mouth are suitable for elderly, 
patients with swallowing difficulties and children (Fu et al., 2004), and in situations where 
portable liquids are not obtainable (Allen et al., 2003). The minute volume of saliva is generally 
enough for disintegration of tablet in the oral tract. The medication is absorbed either partially or 
entirely into circulation systemically from blood vessels surrounded by the sublingual mucosa or 
ingested as a solution to be immersed from the GIT. Sublingual route generally provides a 
quicker onset of action compared to orally taken tablets and the fraction absorbed during the 
blood vessels of sublingual route bypass the hepatic system. The advantages of fast 
disintegrating tablets are increasing and being recognised in academics and in industries (Chang 
et al., 2000). The main approach in developing the fast dissolving tablet is by using super 
disintegrants like sodium starch glycolate (primogel, explotab), cross linked carboxy methyl 
cellulose (croscarmellose), crospovidone, polyvinylpyrollidone (polyplasdone) etc and using 
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highly water soluble excipients (Kucchekar et al., 2003). 
This tablet exhibit a quick and impulsive disintegration in the mouth, when contacted with 
saliva, without alteration from the package; they can be extracted or handled (Schiermeier et al., 
2002). The active ingredient can thus quickly dissolve in the saliva and can be absorbed through 
the membrane it passes, at the time of deglutition, if not sheltered from pre-gastric absorption. 
(Hisakadzu et al., 2002). To perform these needs, tablet must be extremely permeable, 
incorporating hydrophilic substances and should have the ability to quickly absorb water for a 
fast disaggregation of the matrix. Various techniques, like freeze drying, moulding or direct 
compression are at present engaged for the preparation of the formulations in the present 
pharmaceutical market. Honda et al (1998) published that a half of the patients experienced 
trouble in taking medication and felt that tablet was superior and easier compared to other 
formulations like capsules or powders. 
1.1 Characteristics of fast disintegrating systems  
1.1.1. Simplicity of administration 
  Fast disintegrating drug delivery systems are very easy to administer, handle and leads to 
betterment of patient compliance. Generally, aged people experience a lot of difficulty to 
swallow the dosage forms like solutions, suspensions, tablets and capsules due to dysphasia and 
tremors of extremities. This problem can be overcome by using fast dissolving delivery systems. 
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1.1.2 Medicament taste 
Almost all drugs are unpalatable, fast disintegrating drug delivery systems frequently 
containing a medicament in a taste covered form. These drug delivery systems liquefy in the 
mouth of the patient and release the active ingredients as soon as they come in contact with the 
oral cavity. Taste masking of drugs was very important from patient point of view. 
1.1.3 Hygroscopicity 
Most of the dosage forms that dissolve fastly are very hygroscopic and does not maintain 
physical integrity at normal conditions such as humidity which requires special product 
packaging. 
1.1.4 Friability 
Fast disintegrating tablets should dissolve in mouth which are made up of soft-molded 
matrices (highly porous) and compressed into tablets using less compression force, making the 
tablets more friable. It is not easy to handle and requires peel-off blister specialized packaging. 
1.1.5 Mouth fee 
  Feel in the mouth is extremely important and the tablet should give pleasant feel to the 
patient. After disintegration of tablet, large particles that are not soluble or gradually soluble in 
saliva may give a disagreeable gritty feeling. It can be solved by keeping most of the particles 
under the lower size. In some instances, some flavors can enhance an improved perception of 
feeling in the mouth, ensuing that the product is less gritty, yet there is a change in the flavor.  
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Effervescent can also be added to get better mouth feel and helps in disintegration and also 
reducing the dryness of a formulation. 
1.2 Advantages of fast dissolving drug delivery through sublingual route  
  Reduction in the dose there by minimizing the frequency of dosing Heinemann et al, 
1976). Convenient for patients who refuse to swallow the tablet, such as children, elderly people, 
mentally ill, disabled persons, bed ridden patients, renal failure patients, stroke victims and 
uncooperative patients (Indurwade et al., 2002). Convenient way of management and precise 
dosing compared to liquids (Bredemberg et al., 2003).  
   Water is not required to gulp down the dosage form, which is highly suitable for the 
patients who are travelling and having no access to water (Devarajan et al., 2000).  
  Good mouths feel of FDTs which helps to change the fundamental bitter view of 
medication particularly in children.  It provides advantages of liquid medication in solid dosage 
form. Rapid dissolution of drug, which produces fast beginning of action, is absorbed through 
the oral cavity when the saliva passes downwards to the stomach. In these cases the availability 
of drugs to the body is enhanced.  
  Pre-gastric absorption results in increased bioavailability and as a result of reduction in 
doses, medical performance is improved by reducing the side effects. fter administration, it 
leaves minimum or no residue in the mouth (Gole et al., 1993).  
  Conventional low cost packaging and processing equipments are available which are 
compatible with taste masking having pleasant mouth feel. They also show low sensitivity 
towards environmental situations such as temperature and humidity (Bhaskaran et al., 2002).  
INTRODUCTION  
 Padmavathi College of Pharmacy and Research Institute                                                      Page 5 of 93 
 
 New and in the management of life cycle. Stability for longer time, since the medicine 
remains in solid form until it is consumed (Misra et al., 1999).  Enhances tablet disintegration, 
dissolution, drug absorption and onset of effect (Birudaraj et al., 2005).  
  Avoid gastric degradation of the drug in gastric and intestinal environment.  
1.3 Approaches for fast disintegrating tablets 
Conventional technologies for preparing fast dissolving tablets are as follows. 
Lyophilisation (freeze drying) technique.  
Tablet moulding technique  
Spray drying method  
Cotton candy method.  
Mass extrusion technique.  
Sublimation technique.  
Direct compression technique.  
1.3.1 Lyophilization (freeze drying) technique 
Formation of amorphous porous product in freeze-drying procedure dissolves the drug 
rapidly and is exploited in preparation of fast dissolving tablets. Lyophilization is a technique 
that involves removal of the solvent from the drug in frozen solution or in suspension using 
structure-forming additives (Renon et al., 2000). In this process drug solution along with 
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polymer was poured in the preformed blister packs. These trays are then passed through tunnel of 
liquid nitrogen which freezes the drug solution or suspension. These blister packs are then 
charged into the refrigerator to continue for freeze drying. This method established improved 
absorption and increased bioavailability (Jaccard et al., 1985) and also gives glossy structure 
resulting in light weight and highly porous product (Azza et al., 2011). The major disadvantage 
is that this technique is very expensive (Habib et al., 2000), time consuming and fragility which 
makes the formulation unsuitable for conventional packaging for those products which show 
poor stability under stress conditions (Corveleyn et al., 1997). 
1.3.2 Tablet molding technique 
Tablet molding procedure is of two types. The first method (solvent method) consists of 
moistening of the powder bed with hydro-alcoholic solvent followed by compression at low 
pressure to appearance a wetted mass in molded plates i.e., compression molding. From this 
mass the solvent is separated by air drying. The prepared tablets by this method possess porous 
formation that hastens dissolution. The second method (heat molding method) involves 
preparation of suspension by mixing the drug with agar and sugar (manitol or lactose) then 
pouring them in blister packs, solidifying the agar at room temperature  and drying at 30⁰C under 
vacuum. The presence of the binding agents increases the mechanical strength of the tablets 
(Masaki et al., 1995). In this taste masking of the tablets is an additional problem. These drug 
particles were formulated by spray congealing the lecithin molten mixture, polyethylene glycol 
and drug into lactose containing tablet triturate appearance. Similar to the freeze drying 
technique the tablets produced by this technique are easier to develop for industrial 
manufacturing. 
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1.3.3 Spray drying method 
In this procedure gelatin is used as a matrix forming agent, mannitol as a diluent, 
crospovidone, croscarmellose sodium and sodium starch glycollate are used as 
superdisintegrants. The tablets made using this method disintegrated within 20s in aqueous 
media (Allen et al., 1997). Highly porous product was obtained using this method (Allen et al., 
2003). 
1.3.4 Cotton candy method 
This process is also called as candy floss and uses a spinning technique to produce floss-
like arrangement, which looks like a cotton candy. The preparation, involves the formation of 
matrix using polysaccharides or saccharides by repeated action of flash melting followed by 
spinning (Meyers et al., 1995). The matrix which is produced is partly recrystallized to comprise 
enhanced flow properties (Pebley et al., 1994). This candy matrix is then subjected to milling 
process and then blended with drugs, additives and then compressed. This process can hold large 
drug doses and improve mechanical force. However it requires high temperature processing. 
1.3.5 Mass extrusion technique 
This type of expertise involves softening the blend of active ingredient using polyethylene 
glycol and methanol solvent mixture followed by subsequent removal of mass using the extruder 
or by using the syringe to get the product of cylinder into equal segments by using blade that is 
heated to shape into tablets. This cylinder is also used for the coating of granules having 
objectionable taste and thereby masking of bitterness can be done (Bhaskaran et al., 2002). 
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1.3.6 Sublimation technique 
The key in quick disintegration of FDTs is to produce a porous formation in the tablet 
matrix. To make such a porous matrix in the tablets, volatile ingredients are involved in the 
process of sublimation. The ingredients such as ammonium carbonate, ammonium bicarbonate, 
camphor, urea, benzoic acid and naphthalene which are highly volatile can be compressed with 
other additives (Sharma et al., 2010). The volatile ingredients may be removed from the tablets 
by sublimation technique leaving behind a highly porous medium. Cyclohexane or benzene can 
be used for pore forming agents. The tablets prepared by this technique disintegrate in 10 to 20 
seconds (Koizumi et al., 1997). 
1.3.7 Direct compression technique 
This technique is very simple and is generally a cost effective process which can be used 
for the preparation of FDT because of the improved availability of superdisintegrants and sugar 
based excipients (Kumar et al., 2010). 
1.3.8 Superdisintegrants 
Most of the FDT technologies are based on direct compression, using superdisintegrants 
which chiefly affects the rate of disintegration as well as dissolution. The existence of other 
water-soluble excipients and effervescents enhances the process of disintegration further. 
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1.3.9 Sugar based ingredients 
This is one of the methods for preparing FDT by direct compression. They make use of 
bulking agents like mannitol, maltose, sorbitol etc. which exhibit more solubility and sweetness 
which impart taste masking property providing a satisfying mouth feel (Parul et al., 2006). 
Takao et al (2005) classify sugar-based additives into 2 types based on the foundation of 
dissolution rate and moulding. Type-1 saccharides (mannitol and lactose) which reveal less 
mould ability but more dissolution rate. Type-2 saccharides (maltilol and maltose) disclose 
which provide more mould ability and less dissolution rate. In this method disintegration and 
solubilisation of tablet are due to the presence of superdisintegrants, water soluble ingredients 
and effervescent. The disintegration time is satisfactory though the efficiency is powerfully 
affected by the size and hardness of the tablet. 
Conventional equipment, commonly available additives and fewer steps are involved in 
this technique. Elevated doses can be incorporated and the tablet’s final weight can simply 
exceed compared with other techniques. This method is widely used in developing FDTs because 
of the increased accessibility of recipients. 
Addition of disintegrant in FDTs leads to fast breakdown of tablets and therefore, more 
dissolution. Sodium carboxymethyl starch (sodium starch glycollate), cross linked 
polyvinylpyrrolidone (crospovidone), modified cellulose (croscarmellose sodium), soy 
polysaccharides, gellan gum, xanthan gum, cross-linked alginic acid, calcium silicate and ion 
exchange resins are used as superdisintegran ts. FDTs can also be obtained by including 
effervescent disintegrants, which generates CO2. The main disadvantage of effervescent 
disintegrants was its hygroscopic nature. Hence the manufacturers require humidity control 
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conditions and needs to provide safety of the finished product. This reflects by and large the 
price of the finished product. 
1.4 Patented technologies 
1.4.1 Zydis technology 
In this method the drug is made to dissolve (entrapped) in fast dissolving carrier (Seager 
et al., 1998). When these formulations are placed in the mouth, the structure (freeze dried) 
disintegrates immediately and water is required for swallowing (Chang et al., 2000). Gelatin, 
dextran (alginates) was included for the strength of the tablets. Saccharides such as mannital or 
sorbital were added for crystallinity, elegance and hardness. Water is added in manufacturing 
process to get porous tablet and various gums are used for the prevention of sedimentation of 
dispersed drug particles. Collapse protectant such as glycine is included to avoid reduction of 
tablet during freeze drying process. 
1.4.2 Durasolv technology 
CIMA labs contain the Durasolv patented technology. In this technology the tablets 
consist of drug, diluents and a flow promoter. The tablets were prepared by conventional tablet 
punching machine and those tablets can be packed in blisters and this technology is useful for 
products having low amount of active ingredient. 
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1.4.3 Orasolv technology 
This technique is invented by CIMA labs. The taste of active ingredient is masked and 
compressed at low compression forces to have lower dissolution time. The produced tablets are 
friable and soft. 
1.4.4 Flash dose technology 
This technology is originated by Fuisz. Nurofen meltlet which is a mouth tablet of 
ibuprofen uses flash dose technology and is the first product found by Biovail Corporation. 
These tablets contains matrix form self binding clip called as floss and are prepared by flash 
heating process. 
1.4.5 WOW tab technology 
Yamanouchi Pharmaceutical Company patented this technology. In this procedure, high 
and low moldable saccharides are used to get a strong tablet having fast melting. The active 
ingredient is mixed with lactose, mannitol, glucose and granulated with maltose, oligo 
saccharides and then compressed to get tablet. 
1.5 Taste masking 
Many techniques exist for covering the drug’s bitter taste which includes taste masking with 
flavouring agents, sweetening agents and amino acids. Masking of taste is done by various 
methods such as polymer coating, conventional granulation. 
 
INTRODUCTION  
 Padmavathi College of Pharmacy and Research Institute                                                      Page 12 of 93 
 
1.5.1 Taste masking using sweetening agents, flavouring agents and amino acids 
This method is used for masking of taste in chewable tablets and fluid preparations 
(paediatric) and is not useful for extremely harsh and water soluble drugs. Artificial flavouring 
and sweetening agents are usually worn with other taste-masking methods. The cooling effect of 
the taste masking agents helps in reducing the objectionable bitter taste. Menthol decreases the 
bitterness. Aspartame is a well-known sweetener in reducing the bitterness. A minute 
concentration i.e., 0.8% is useful in reducing the harsh taste of acetaminophen. Mannitol, starch, 
and lactose provided taste-masking of caffeine (Matsubara et al., 1990). 
Artificial sweeteners like hesperidin dihydrochalcone 4’-β-D glycoside and neohesperidine 
dihydrochalcone have the capacity to cover bitter and salt tastes with lingering sweetness in 
them. 
1.5.2 Taste masking using lipophilic vehicles 
Poly-alcohols and lipids raise the mouth viscosity due to which the taste buds are coated 
and are called potential taste masking agents. 
1. Guaifenesin melts granulation carnauba wax and veegum (magnesium aluminium silicate)  
2. Cimetidine granulation GMS (glyceryl monostearate)  
 Lecithin and lecithin-like substances have power over objectionable taste in 
pharmaceuticals. Veegum along with soy lecithin is used to cover the disagreeable talampicillin 
hydrochloride taste. The drug is either dissolved or dispersed into chloroform. 
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1.5.3 Taste masking using hydrophilic vehicles 
In this method drug particles possess a barrier in the form of coating, thus the drug and 
taste buds’ interaction minimizes. Chewable tablets upon coating provide exceptional taste 
masking. Micro emulsion technique is used for masking the taste of the powders, chewable 
tablets and liquid formulations. 
1.5.3.1 Carbohydrates 
Orally given drugs can be taste masked by covering with carbohydrates. The bitter tasting 
drugs like pinaverium bromide, does not have objectionable taste when formulated by coating 
with cellulose or shellac mixture with polymer. 
Masking the bitter taste of ibuprofen has been effectively done by air-suspension method 
to get microcapsules, which consist of core of crystalline ibuprofen along with eudragit coated 
chewable taste-masked character (Shen et al., 1996). 
1.5.4 Taste masking using inclusion complexation 
The drug molecule enters the opening of a complexing agent and forms stable complex. 
This agent is capable enough for covering the objectionable feel of drug by diminishing the oral 
solubility on swallowing, thus reducing the awareness of bitterness in taste. This technique is 
appropriate for lower doses of drugs. The Vander Waals forces are occupied in inclusion 
complexes (Nanda et al., 2002). β- cyclodextrin is used as a complexing agent which is sweet in 
taste, non-toxic and cyclic oligosaccharide which is obtained from starch. 
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The bitterness of carbetapentane citrate (syrup) was condensed to 50% by making 1:1 
complex (cyclodextrin). Pleasant ibuprofen solutions are formed at 1:10 to 1:15 ratio with 
ibuprofen and hydroxypropyl β-cyclodextrin. The complex covered the bitter factor but produced 
sore taste, which was covered by sweetening agents. 
1.5.5 Taste masking using ion-exchange resins (IERs) 
These are high Mol. Wt. polymers having both cationic and anionic functional groups. 
These resins are mainly used in formulations for stabilizing the sensitive components, delaying 
in release of drug, breaking up the tablets, and to cover the taste. Drug can be incorporated by 
exposing the resin to the drug repeatedly in a chromatographic column or increasing the contact 
of resin within drug solution. 
  There is an attachment of drugs to the resin substrate thus forming insoluble resonates by 
means of ionic bonding; there by separation of the drug-resin complex does not take place below 
the salivary pH environment. This properly masks disagreeable taste and odor of the drugs. 
  The release of drug from the resin is complex and dependent on the resin properties and 
the ionic surroundings within the GIT. The drug molecules that are in attachment with the resin 
are exchanged with ions that have charge are present in the GIT and diffused out of the resins. 
1.5.6 Taste masking using miscellaneous approaches 1.1.5.6.1 Effervescentagent 
Effervescent agents were useful and are beneficial for oral management of drugs. They 
are used for masking the taste for dosage forms that have no intention to dissolve in water earlier 
to administration. A composition of chewing gum with objectionable taste medicament was 
formulated in such a way that it provides the medicament to the oral track. It consists of a base of 
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gum, an orally takable active ingredient, a taste masking agent (CO2), a composition of optional 
desensitization (anaesthetics like benzocaine, etc.) and other inactive materials, such as 
organoleptic additives and bulking agents. Recently, fentanyl and prochlorperazine effervescent 
tablets were formulated to supply these drugs for absorption to the oral tract. 
1.5.6.1 Salt preparation 
Salt preparation is one of the classical approaches to cover the bitter drug taste by either 
decreasing solubility or by increasing hydrophobicity by reducing contact of bitter drugs with the 
taste buds. This approach differs from others to alter the chemical composition of the drug 
substance to make it less soluble in saliva and therefore less stimulating the taste buds. Addition 
of alkaline metal bicarbonate like NaHCO3 covers the disagreeable taste of ibuprofen in watery 
medium. Objectionable taste of caffeine can be covered by forming as carbonated oral solid 
dispersion. Aspirin tablets are made bland by preparing aspirin in magnesium salts form. 
1.5.6.2 Solid dispersion technique 
In this technique, one (or) more drugs are spread in an immobile solid carrier. Solid 
dispersion of drug with the aid of polymers, sugar, or other appropriate agents is very practical 
for taste masking. The dimenhydrinate masking of bitterness can be done by formulating the 
solid dispersion of drug with polyvinyl acetate phthalate. 
1.5.6.3 Group modification and pro-drug approach 
The clarithromycin 2’ position’s alkyloxyalkyl carbonates have covered bitterness and 
enhanced bioavailability when given orally. Bland pro-drug of opioid drugs can be formulated 
for better buccal release. Bitter prodrugs of nalbuphine hydrochloride, naltrexone, naloxone, 
INTRODUCTION  
 Padmavathi College of Pharmacy and Research Institute                                                      Page 16 of 93 
 
oxymorphone hydrochloride, butorphanonol, and levallorphan can be manufactured for buccal 
route of administration to get better bioavailability comparative to oral dosing devoid of 
objectionable taste. 
1.5.6.4 Freeze drying method 
This technology is used in developing fast-dissolving ODTS like Zydis and Lyoc 
technology. As the freeze drying process produced high porosity, Zydis in its tablet shaped 
dosage form disassociates in the mouth within seconds. 
  In Zydis process the drug has to be dissolved in a water soluble structure forming agent. 
The mixture is then placed into the blister pockets and then freeze dried. Gelatin and manifold 
are most commonly used structural ingredients, starches and gums are the other suitable 
excipients. This process is preferred in low solubility drugs which are easily freeze dried. 
1.5.6.5 Wet spherical and continuous melt method 
To cover the bitter taste of enoxacin, this method of micro encapsulation process 
combined with this method was used. 
1.6 Mechanism of tablet disintegration and water absorption 
When mouth dissolving tablets are placed in the mouth, upon contact with saliva the 
tablets disintegrate or dissolve instantaneously. There are four mechanisms involved in the tablet 
disintegration mechanisms 
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Swelling  
Wicking  
Deformation  
Disintegrating particle/particle repulsive forces  
1.6.1 Swelling  
The most commonly established mechanism of tablet breakup is swelling. The tablets 
with elevated porosity confirm poor disintegration because of lack of sufficient swelling force 
and on the other hand in tablets with low porosity, the swelling force is sufficiently exerted. The 
fluid cannot be penetrated into the tablet when the packing fraction is more, there by 
disintegration rate slows down. 
1.6.2 Wicking 
Capillary action mechanism is the first step in wicking. When the tablet is placed in the 
medium, it penetrates into the tablet and the air is replaced on particles, weakening 
intermolecular bond and tablet breaks into finer particles. The water taken by the tablet depends 
up on the hydrophilicity of the drug or ingredient and on surroundings of tabletting. For this type 
of disintegrants, porous structure maintenance, less interfacial tension in the direction of aqueous 
fluids are compulsory which creates a hydrophilic network around drug particles and helps in 
disintegration. 
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1.6.3 Deformation 
During compression of tablet, the disintegrated particles deform and these particles obtain 
normal structure when they are contacted with aqueous media. When granules are deformed 
expansively during compression, the swelling ability of starch is enhanced. The deformed 
particles increase in size and produce a breaking of the tablet. The starch may be followed by this 
deformation mechanism and has to be studied. 
1.6.4 Disintegrating particle/particle repulsive forces. 
Guyot-Hermann has projected repulsion theory of a particle that non-swelling particles 
also cause disintegration of tablets. The mechanism of disintegration is due to electric repulsive 
forces between particles and in order to have that repulsive forces water is required (Lachman et 
al., 1990). This mechanism of repulsion is secondary to wicking. 
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2.0 AIM AND OBJECTIVES 
In the present study the main objectives were 
To develop fast disintegrating sublingual tablet formulations using zolmitriptan and 
rizatriptan (5-HTIB/ID receptor agonist) anti-migraine drugs. 
To evaluate the powder formulations for Micromeritic properties. 
To determine prepared tablets for physical parameters, in vitro release studies and 
characterization of optimized formulation. 
To establish the stability of optimized formulation. 
To compare in vivo release studies using rabbit as the animal model. 
RESEARCH WORK PLAN 
Literature review  
Selection of excipients  
Selection of superdisintegrants 
Preparation of fast disintegrating sublingual tablets  
Evaluation of sublingual tablets  
Micromeritic properties of prepared powder formulations  
Determination of physical properties of tablets  
In vitro release studies  
Characterization  
Stability studies  
Documentation of the results  
     Summary 
Conclusion 
AIM AND OBJECTIVES   
 Padmavathi College of Pharmacy and Research Institute                                                      Page 20 of 93 
 
3.0 LITERATURE REVIEW 
  Azza et al., (2011) developed fast disintegrating sublingual zolmitriptan tablets using 
freeze drying technique. They used gelatin as binder and manitol as matrix enhancing agent. The 
tablets disintegration and dissolution is enhanced with speeding the onset and drug absorption. 
This sublingual formulation gave faster and higher zolmitriptan plasma concentration in rabbits 
compared with oral marketed zolmitriptan formulation and constitutes an advance in migraine 
treatment.  
  Alessandro et al., (2010) have written a review on migraine. They described strong 
epidemiologic evidence linking migraine and stroke in adults. In their review four major issues 
are summarized. 1. Migraine ischemic stroke relation 2. Migraine with increased cardiovascular 
risk factors 3. Migraine specific drugs 4. Migraine and ischemic vascular events.  
  Debjet et al., (2009) wrote an overview on fast dissolving tablets. In that review they 
explained the tablets fast disintegration and dissolution in saliva without water within few 
seconds. They also explained the need of FDTs, their benefits, limitations, techniques for 
preparation of tablets, patented technologies, commercially available formulations, mechanisms 
of superdisintegrants, pre-formulation studies and the evaluation of those prepared tablets. They 
concluded that the problems experienced by the patients with conventional tablets can be 
overcomed by fast dissolving tablets.  
   Mohanachandran et al., (2011) made an overview on superdisintegrants. They 
described about the use of right disintegrates in order to have optimal bioavailability and to 
improve the efficacy of solid dosage forms. Generally superdisintegrants were used at low 
concentrations typically 1-10 % compared with the total formulation weight. In their review they 
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listed the various superdisintegrants being used in formulations which provide effective and safer 
delivery to the patient.  
  Shailesh Sharma et al., (2007) wrote a review on fast dissolving tablet: the future of 
compaction. They explained about the convenience of the fast dissolving formulations.  
  Avani et al., (2006) explained difficulties of swallowing conventional tablets and 
demands for orally disintegrating tablets particularly in children and in old age patients.  
  Sheeba et al., (2009) studied the effect of rising nifedipine load on fast disintegrating 
sublingual characteristics in emergency treatment of hypertension. This drug undergoes 
presystemic metabolism in the liver and gut wall. The bioavailability was found to be between 
43%-77%. They prepared sublingual tablet as it bypasses the metabolism of the drug in liver so 
that the patient gets immediate relief from hypertension. In the preparation of sublingual tablet 
used various superdisintegrants. The Tablet was formulated using the direct compression 
technique. The evaluation tests of the prepared tablet was found to be satisfactory. The tablet 
have mixture of croscarmellose sodium and sodium starch glycolate, each 2mg showing fast 
dissolution and disintegration.  
  Mutasem et al., (2006) determined the epinephrine drug concentration from fast 
disintegrating tablets. The plasma concentrations are same as dose obtained after 0.3mg IM 
injection. They compared 0, 10, 20 and 40mg of epinephrine in sublingual tablets compared with 
0.3mg intramuscular epinephrine injection, they used rabbit model for the study. They concluded 
that the tablet containing 40mg of drug in sublingual formation shows same results as that of 
0.3mg intramuscular injection. So this shows  that  sublingual  administration  is  one  of  the  
feasible alternatives to intramuscular injection. 
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  Elina et al., (2011) investigated improvement of absorption of less water soluble, first-
pass metabolised perphenazine with sublingual formulation. In order to increase the absorption 
they have included cyclodextrin and made solid dispersion which increases the solubility of 
sublingual formulation. They proved that sublingual absorption is further enhanced by 
micronization of perphenazine.  
  Toshihiro et al., (2003) developed lansoprazole fast disintegrating tablets which consist 
of enteric coated micro granules and inactive granules. They used manitol as the main excipient, 
HPC, microcrystalline cellulose and cross povidone as binders and disintegrants. They concluded 
that the tablet containing 47.4% of enteric coated micro granules gave sufficient strength and 
rapid disintegration in the mouth (<30s) and also did not show much effect in the acid or buffer 
stages of dissolution.  
  Emma et al., (1998) conducted pharmacokinetic studies on 2.5mg and 5mg oral doses of 
zolmitripton in women and men. They compared pharmacokinetics in women and men. The 
absolute bioavailability was found to be 0.41 and 0.09 after 2.5mg and it was found to be 0.48 
and 0.36 after 5mg in women and men respectively. The AUC after 2.5mg dose was found to be 
18.4hng/ml and 23.1hng/ml correspondingly, in men and in women. The AUC after 5 mg dose 
was found to be 32.7hng/ml and 60.2hng/ml respectively. They concluded that these differences 
do not have clinical significance. The AUC and C-max depends on dose and as a mean it was 
fallen 13% and 16% respectively when the drug is administered after taking food. They 
concluded that the oral bioavailability was good at therapeutic doses in healthy humans and also 
proved that dose dependent pharmacokinetics does not affect the presence of food to clinical 
extent.   
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  Acharjya et al., (2010) developed three simple, accurate, precise and inexpensive UV 
methods. The drug exhibited maximum absorption at 0.5-20 µg/ml concentration at 227 nm and 
at the concentration of 0.5 to 8.0 µg/ml at 281 nm respectively. 
   They  derivatized spectrum into 1st and 2nd order. The trough at 233 nm for D1 and crest 
at 238 nm for D2 were measured. From these two  methods the drug showed linearity from 0.5-
20 µg/ml. They concluded that this method shows good results in the concerning  concentration  
range,  accuracy,  precision,  robustness  and ruggedness. 
  Sameer et al., (2009) studied presence of calcium silicate and lubricants on β-
cyclodextrin based FDTs. They also evaluated the effects of moisture at 75, 85 and 95% RHs. 
They used factorial design to optimise the concentrations of calcium silicate as disintegration 
enhancing agent and magnesium stearate as lubricant. In the results they have concluded that the 
concentration of calcium silicate does not have any effect but though the presence of lubricant 
was very significant for degeneration and rigidity of the tablet. They found 1.5 percent of 
magnesium stearate gave 23.4seconds DT and hardness as 1.2kg. They also concluded that at 
75% moisture the hardness does not have any effect where as at 85% and 95% treatment with 
moisture, the hardness of the tablet was increased. However the disintegration time was not 
effected.  
 Anupama et al., (2009) developed mouth dissolving tablets of oxcarbazepine to get 
desired and intended benefits. They used direct compression technology and solid dispersion 
method. In the first method they have used crospovidone and aspartame. In solid dispersion they 
used polyvinyl pyrrolidone K-30; PEG 6000 in various weight ratios. They concluded that solid 
dispersion technology was the better substitute to the direct compression technology for the 
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development of mouth dissolving tablets especially for the drugs that are less soluble in water.    
  Arjun et al., (2010) prepared rosiglitazone mouth dissolving tablets in diabetes mellitus 
for long therapy. Sodium starch glycollate, crospovidone and croscarmellose sodium were used 
as super disintegrants. The mouth dissolving tablets having 1:1 ratio of cros carmellose sodium 
and crospovidone showing maximum release of the drug. They also conducted stability studies at 
40⁰C/75% relative humidity. The formulations were stable.  
  Honey et al., (2008) optimised and formulated fast disintegrating tablets of ondansetron 
HCI or domperidone using aminoacetic acid, carmellose and sodium alginate to prevent nausea 
and vomiting. They revealed that domperidone optimised FDTs better than domperidone FDTs 
containing cross carmellose or crospovidone. They concluded that this novel mixture of 
excipients can be used for deliverance of water insoluble drugs instead of superdisintegrants. 
Shapero et al., (2006) studied clinically an international open- label study. It includes new, 
substantial variables applicable to PCPs and recruits patient’s present prime care who diagnosed 
migraine. They treated migraine attack/month with zolmitriptan ODT 2.5mg. 595 patients are 
treated with 7171 migraine attacks with ODT tablet. Out of those 504 of them finished six 
months questionnaire, 380 patients still wish to continue ODT tablet. From this study they 
indicated that patient-oriented end-points are significant and encouragable to the physicians than 
conventional end point, making them to decide on their own managing the migraine.  
  Rahul et al., (2009) studied and optimised fast disintegrating tablets in three stages and 
in each stage hardness, friability and disintegration time was studied and they revealed that in 
stage-I hardness and disintegration time improved with increased gelatine concentration. In 
stage-II saccharides like sorbitol, mannitol and sucrose in different ratios were added (10 percent 
LITERATURE REVIEW  
 Padmavathi College of Pharmacy and Research Institute                                                      Page 25 of 93 
 
and 80 percent), good results were obtained with mannitol containing formulations which was 
carried for the next stage and in that stage (stage III) they have added polymers to enhance 
mouth feel and pre-gastric  withholding  (carbopol  974P-NF).  Pluronic  F127  (6%)  showed 
increased disintegration time and viscosity without any change in mechanical properties. 
  Takao et al., (2005) studied on the improvement of compressibility of low compressible 
saccharides; modification of the particle was done by coating and granulating the low 
compressible saccharide with a high one. They also discovered that high compressible 
saccharides can also be used as a binder solution in the amorphous state after the completion of 
granulation stage. They concluded that the prepared tablets have sufficient hardness, fast 
disintegration time, manufactured by simple commonly available equipment and used for wide 
range of drug dosages.  
  Mutasem et al., (2006) have developed sublingual tablets of fast disintegrating 
epinephrine tablets. They have prepared four formulations with 0 percent, 6 percent, 12 percent 
and 24 percent of epinephrine bitartrate. The excipients used were MCC (PH-301), low-
substituted HPC (LH11) and magnesium stearate and tablets were obtained by direct 
compression method. These tablets had been evaluated for physical parameters. In all the 
formulations hardness, disintegration time and wetting time was found to be suitable for 
sublingual administration.  
 Takuma et al., (2008) made an effort to produce fast disintegrating furosemide tablet 
using direct compression method. They used MCC, cros carmellose sodium, xylitol and sucrose 
stearic acid ester. The tablets produced using sodium starch glycollate by solvent (organic) 
evaporation technique and showed hardness >30 N and disintegration time was < 20s which was 
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concluded by them to be suitable for preparing fast disintegrating tablets.  
 Yara et al., (2009) evaluated bioequivalence of two commercial ondansetron 8mg 
tablets. They have used simple, sensitive, rapid, LC-MS method of ondansetron for 
determination in human samples. Bioequivalence between both was determined by 90% 
confidence interval for the Cmax ratios of AUC for the test and the reference products. They 
concluded that the test as well as reference formulations are bioequivalent.  
  Kilic et al., (2007) developed a specific and sensitive LC-MS method for zolmitriptan 
and their metabolites determination in human samples. The internal standard and analytes 
(paroxetine) were extracted with ethyl acetate: dichloromethane (4:1) and were separated using 
isocratic mobile phase in XTerra RP18 column. This validated method was used in 
pharmacokinetic studies. The mobile phase consists of acetonitrile, 5mM ammonium acetate and 
formic acid (50:50:0.053, vole/vole/vole).  
  Vijayakumar et al., (2010) developed a sensitive, specific, linear, stability indicating 
Hp-LC method for the analysis of zolmitriptan related substances. They concluded that this 
method is used for detecting, quantifying impurities (known and unknown) and degradation 
products during routine analysis of zolmitriptan and stability studies.  
  Asad et al., (2007) developed simple, rapid, gainful and extraction gratis 
Spectrophotometric method for zolmitriptan determination in formulations. In this method they 
made a reaction of zolmitriptan in acetonitrile with 0.2% 2, 3-dichloro-5, 6-dicyano-1, 4-
benzoquinone to form a colour product and showed absorbance at 555 nm. They concluded that 
this method can be used for determination of zolmitriptan in formulations.  
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  Sharma et al., (2010) prepared MDTs of domperidone using camphor and crospovidone 
with the help of direct compression method. By exposure to vacuum the camphor was sublimed. 
These tablets were subjected for friability and disintegration time. They found that the tablets 
with optimum concentrations of camphor and higher percentage of crospovidone results in rapid 
disintegration.  
  Kumar et al., (2010) developed mouth dissolving tablets of sildenafil citrate using CCS, 
CRP, MCC and starch by direct compression method. They concluded that tablet containing 
crospovidone and croscarmellose sodium between 2-8% was disintegrated quickly (30s).    
  Prashant et al., (2010) developed and evaluated mouth dissolving meloxicam tablets. 
The tablets were manufactured by wet granulation. The ingredients used were crospovidone, 
colloidal silica dioxide, camphor, lactose and PVP solution in ethyl alcohol. The prepared tablets 
were subjected for physical tests. They found that the formulation containing camphor and 
rospovidone effects the parameters like wetting time, disintegration time and percentage 
friability and also concluded an effective vacuum drying technique which is an important 
alternative approach in place of more expensive adjuvant. 
  Takao et al., (2008) developed taste masked fast disintegrating famotidine tablets using 
spray dry method. The excipients used were aqua coat ECD30 and Eudragit NE30D or triacetin. 
They established that the spray dried process produced flavour masked particles for FDTs.  
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NEED FOR INVESTIGATION 
  The require for patient compliance dosage forms were increased since last decade. This 
has lead to the development of new techniques. The development of new drug formulations is 
time consuming and expensive these days. So increased efforts is a challenge for researchers in 
producing cost effective dosage forms for the development of new dosage forms using existing 
drugs. Currently tablets and capsule dosage forms are available as drug delivery systems. 
However, patient groups like geriatric, paediatric, mentally retarded and uncooperative will not 
prefer to take conventional dosage forms (Prajapati et al., 2009). To fulfil these needs the 
researchers have invented novel oral dosage forms known as fast disintegrating tablets that 
disintegrate quickly in the saliva within few seconds without using water. Sublingual route of 
administration produces quicker commencement of action than conventional tablets and part 
absorption from the blood vessels of sublingual route bypasses the first pass effect (Birduraj et 
al., 2005). 
  Various methods are used to devise fast disintegrating tablets (Allen et al., 2003).One of 
the easiest and cost effective tablet techniques which require incorporation of superdisintegrants 
and highly water soluble excipients to get fast disintegration and dissolution. Water or heat is not 
required in this technique during preparation and it is most ideal for drugs which are moisture 
and heat sensitive. 
  Migraine affects 6% in males and 18% in females with 34 attacks per year for men and 
37 attacks per year for women (Lipton et al., 1993; Hu et al., 1999). It is characterised by 
unilateral, pulsating moderate to severe headache (Fenuik et al., 1985; Stovner et al., 2006), 
commonly accompanied by nausea, vomiting, phonophobia and photophobia (Zimma et al., 
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2011). The attack lasts for 4-72 hrs in adults (Launer et al., 1999). Two types of migraine are 
identified i.e., migraine with aura and migraine without aura. Major issues considered in 
migraine are cervical artery dysfunction (Hedlund et al., 2009), increased prevalence of 
cardiovascular risk factor caused due to migraine specific drugs (Lipton et al., 2004), analgesic 
over doses, refractory migraine, migraine in elderly, during pregnancy and menstrually triggered 
migraine. It is believed to be due to the release of serotonin chemical or 5HT to the blood stream 
from its storage site resulting in changes in neurotransmitter and blood vessels in the brain. This 
causes pain in neurons and the blood vessels wall become irritated. 
  Zolmitriptan is class-III drug, serotonin 5-HT receptor agonists and  widely used in the 
treatment of migraine. The symptoms of migraine include pain, nausea and photophobia or 
phonophobia (Marcelo et al., 2003). This drug is completely absorbed followed by oral 
administrations. The therapeutic activity of the drug is due to agonist effect at the 5-HT IB/ID 
receptors on intra cranial blood vessels, trigeminal system sensory nerves which causes 
constriction of cranial vessel and the inhibition of release of pro-inflammatory neuropeptide. 
Some triptans are available by means of various routes of administration apart from oral tablets 
like ODTs, rectal suppositories and intranasal administration, etc. Current methods of 
administering anti-migraine drugs suffer from major efficacy limitation due to degradation in the 
GIT and low absorption of the drug. Oral formulations of anti-migraine drug has large doses (20-
30mg) leading to nausea, vomiting and other adverse effects. Most of the anti-migraine drug is 
subjected to first pass metabolism. Low bioavailability and slow onset causes the drug to be 
completely absorbed following oral administration of action and large inter-subject variability.  
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Injectable forms need lower dose as related to other non-injectable methods of administration 
which causes inconvenience of an injection and problems with the self administration are self 
evident. 
3.1 Advantages of sublingual route. 
Enhances tablet disintegration and dissolution  
Speeding drug absorption and onset of effect  
Avoid first pass hepatic metabolism  
Avoid gastric irritation, nausea and vomiting  
Reduction in the dose there by minimizing the frequency of dosing  
Convenient for administering to children and elderly people 
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3.1 DRUG PROFILE 
 
Zolmitriptan  
 
  Zolmitriptan belongs to selective 5-hydroxytryptamine 1B/1D  receptor agonist. 
 
Structure: 
 
H3C CH3 
 
N 
 
 
 
 
 
 
O 
 
N 
O H N 
H 
 
 
 
 
 
IUPAC name: (S)-4-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl] methyl]   xazolidinone. 
 
CAS NO: 139264-17-8. 
 
Mol. For.: C16H21N3O2. 
 
Mol. Wt.: 287.36 gm/mol. 
 
Phy. State: White or almost white powder. M.P: 136 to 141⁰C. 
 
Category: Anti-migraine 
 
Solubility: Slightly soluble in water and freely soluble in 0.1M HCL. Dose: 2.5mg, 5mg up 
to10mg (maximum). 
 
Half life: 2 to 3 hours. 
 
Bioavailability: Approximately 40% absolute bioavailability. Absorption: Well 
absorbed through GIT. 
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 3.2.1 Metabolism: It is converted into N-desmethyl metabolite which is active such that the 
concentration of metabolite is about 2/3rd of zolmitriptan as the strength of metabolite is 2-6 
times that of parent and contributes a major part on the whole effect after zolmitriptan 
administration (Dowson et al., 2005). 
 
3.2.2 Adverse effect: Tightness in the chest, bluish tongue to the skin, cold arms and legs, 
dizziness, drowsiness, rashes on skin, swelling of the eye lids or face, smallness of breath. 
 
Stability: Stored at room temperature, protected from heat, moisture and sunlight. 
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3.2 POLYMER PROFILE 
3.2.1. Sodium starc h glycollate 
Pregelatinized  starc h occurs as moderately coarse to fi nd powder, white to off-white in colour, 
odourless with slight characteristic taste. 
Mol. for: (C6H10O5)n. Non-proprietary 
names: BP: Pregelatinized starch 
PhEur: Amylum preg elificatum  
USPNF: Pregelatinize d starch. 
Synonym: Compress ible starch, lycatab C, Instastarch, lycatab PGS, merigel. 
CAS No.: 9005-25-8 
Che. name: Sodium carboxymethyl starch 
Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Category: Tablet and capsule diluent, disintegrant and binder. 
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  Applications in pharmaceutical technology: Widely used as binding agent, diluents and 
disintegrating agent in tablet an d capsule formulations (Jarosz et al., 1982), it is used as a binder 
in tablets  
   (Suzuki et al., 1976). In those formulations, this pregelatinized starch is self lubricating. 
When it is used with other excipients there is a need of adding lubricant (Pilpel et al., 1971). 
Pregelatinized starch can also be used in wet granulation process.  
Tablets prepared with this have good storage properties (Gordon et al., 1990) and are 
stable. It is stored in properly closed container and protected from moisture and temperature. The 
physical nature of sodium starch glycol late remains unchanged for 3-5 years at moderate 
temperatures and humidity. 
Incompatibilities: Incompatible with ascorbic acid (Botha et al., 1987). Safety: SSG is 
extensively used in oral formulations and is considered as non-hazardous and non-irritant 
material. 
3.3.2 Croscarmellose sodium 
Croscarmellose sodium is a cross linked sodium carboxymethyl cellulose polymer. 
Nonproprietary names: 
Croscarmellose sodium- BP  
Carmellosum natricum conexum- PhEur  
Croscarmellose sodium- USPNF \ 
Synonym: Ac-Di-Sol; cross linked carboxymethylcellulose sodium; Explocel; cellulose gum 
modified; Nymcel ZSX; Pharmacel XL; Primellose;  
Che. name: Cellulose, carboxymethyl ether, sodium salt, cross linked  
CAS No.: 74811-65-7  
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Molecular weight: 9 0,000 to 70,000 
Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
Category: Tablet and capsule disintegrant. 
 
Applications: 
 
It is used as disintegrates in granules, tablets and capsules (Dahl et al., 1991; Ferrero et 
al., 1997). In tablet formulations, it may be used in dry and wet methods. In wet granulation 
process, the croscarmellose sodi um can be included in both stages, so that the wicking, swelling 
ability of the croscarmellose sodium is utilized (Gordon et al., 1993 ). Up to 5% w/w 
concentrations can be used as disintegrant, but no rmally  2% w/w was used in the tablet s which 
are prepared by direct processes of manufacturing and concen tration 3% w/w can be used for 
wet-granulation method. 
Physical Description: 
White or greyish-white odourless powder. 
Storage conditions: 
  Though it is a hygroscopic material but is stable. It must b e stored in a cool, dry place in 
a well closed container. 
Safety: 
Mainly used as a disintegrant in oral formulations and is nontoxic and non-irritant 
material. 
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3.2.3 Crospovidone 
 
  Synthetic photopolymer of N-vinyl-2-pyrrolidinone. 
 
Nonproprietary name: 
 
BP: Crospovidone  
 
PhEur: Crospovidonum  
 
USPNF: Crospovidone Synonym:  
 
Cross linked povidone; E1202; Kollidon CL-MPolyplasdone XL- 10; Kollidon CL; 
polyvinylpolypyrrolidone; PVPP; Polyplasdone XL; 1-vinyl-2-pyrrolidinone homopolymer.  
 
Che. Name:  1-Ethenyl-2-pyrrolidinone homopolymer CAS No.: 9003-39-8  
Mol. Formula: (C6H9NO)n  
Mol. weight: 1 000 000  
 
 
 
Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
Category: Tablet disintegrant. 
 
Applications: 
 
As tablet disintegrant, dissolution agent (2–5%) in ta blets which are prepared by direct, 
wet and dry processes (Hipasawa et al., 2004). It quickly shows high capillary action and 
pronounces hydration capacity, with sma ll tendency in gel formation. The big particles exhibit a 
quicker disintegration than smaller once. It can also be used for enhancing solubility. 
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Physical description: 
 
White or Off-white free-flowing tasteless, odourless hygroscopic material. 
 
Storage conditions: 
 
  Hygroscopic, stor ed in closed airtight container in a dr y and cool place. 
 
Incompatibilities: 
 
  Compatible with mo st organic and inorganic excipients, when it is contacted with water, 
crospovidone form molecular adducts with other materials. 
 
Safety: 
 
Used in oral products and is considered as a nontoxic, non- irritant. 
 
 
3.2.4 Microcrystalline cellulose (Avicel pH102) 
 
Purified partially polymerized cellulose 
 
Nonproprietary name:  
Microcrystalline cellulose- BP  
Microcrystalline cellulose- JP  
 
Cellulosum microcristallinum- PhEur  
 
Microcrystalline cellulose- USPNF Synonym:  
 
Avicel PH; cellulose gel; Celphere; Celex; Ceolus KG; E460; Emcocel; Ethispheres; Fibrocel; 
Pharmacel; crystalline cellulose; Tabulose; Vivapur.  
 
Che. Name: Cellulose CAS NUMBER: 9004 34-6  
 
Mol. For: (C6H10O5)n where n=200.  
Mol. Weight: 36,000.  
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Structure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Category: 
 
  Adsorbent; suspending agent; diluent for tablets, capsules and as a disintegrate for table. 
 
Applications: 
  Widely used as binder, diluent in formulations of tablet and capsule. In tablets it is used 
in both compression techniques (Wallace et al., 1983). In addition to this it also used as lubricant 
and disintegrant (Omray et al., 1986) in tablet manufacturing. Microcrystalline cell ulose is also 
used in cosmetic formulations and in food products. 
Physical description: 
White, odorless, tasteless, crystalline powder having porous particles. 
Storage conditions: 
Though it is hygroscopic material but it is stable. This should be stored in a cool and dry 
place preferably in air tight container. 
Safety: 
It is commonly used in oral, food products and is co nsidered as nontoxic and non-irritant. 
Consumption of huge quantitie s may havelaxative effect, although it is not having problem 
when included in pharmaceutical formulations as an excipient (Cooper et al., 1983). 
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3.2.4 Mannitol (D-mannitol)  
It is a hexahydric alcohol associated with mannose and is  isomeric with  sorbitol.  
Mol. formula: C6H14O6.  
Mol. weight: 182.17 
Category: Sweetening agent, diluents for tablets and capsule, tonicity agent, vehicle for 
lyophilized formulations. 
Description: 
White, odorless, crystalline or free flowing granules. It is having sweet taste and the 
sweetening powder is similar to glucose and half sweet as sucrose and also gives cooling 
sensation in the mouth. Mannitol shows polymorphism phenomenon. 
Application: 
In pharmaceutical preparation it is chiefly used as a tablet diluting agent (10-90%). 
3.2.5 Aspartame 
Nonproprietary names: 
BP  : Aspartame  
PhEur  : Aspartamum  
USPNF :Aspartame 
Che. Name :  N-α-l-Aspartyl-l-phenylalanine 1-methyl ester  
Structure: 
 
 
 
 
 
Category: Sweetening agent. 
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Applications: 
It is intensely used as a sweetening agent in beverage products, food products, in 
pharmaceutical preparations includ ing tablet formulations (Joac him et al., 1987), powders and 
in vitamin preparations. It improves flavour and it can be used to co ver some of the disagreeable 
t aste characteristics. This has 180-200 times sweetening power compared to sucrose. 
Storage conditions: 
  It is stable in dry conditions. Hydrolysis occurs due to the presence of moisture and forms 
l-Aspartyl-l-phenylalanine , 3-benzyl-6-carboxymethyl-2, 5-diketopiperazine and β-l-Aspartyl-l-
phenylalanine methy l ester. 
Safety: 
Aspartame is most widely used in oral pharmaceutical dosage formulations, in bev erages, 
and in food preparations as a powerful sweetener and is considered as nontoxic material. The W 
HO has set suitable daily dose ingestion for aspartame at 40 mg/kg b ody-weight (FAO/WHO 
1981). 
3.2.6 Magnesium stearate  
  It consists of mixture of solid organic acids containing variable portions of stearate and 
palmate of magnesium.  
Nonproprietary name: 
Magnesium stearate- BP  
Magnesium stearate-JP  
Magnesii stearas-PhEur  
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Synonym:  
  Magnesium octadecanoate, magnesium salt, octadecanoic acid, stearic acid and 
magnesium salt.  
Chemical name: Octadecanoic acid magnesium salt. CAS No.: 557-04-0  
Stru. Formula: [CH3 (CH2)16COO] 2 Mg. Mol. Weight: 591.34  
Category: Lubricant for tablet, capsule.  
Applications:  
Magnesium separate was commonly used in cosmetics, pharmaceuticals and in food 
industry. It is chiefly used as flow promoting agent in capsule, tablet manufacturing at 0.25% 
w/w and 5.0% w/w concentrations. It is also found as an excipient in barrier cream.  
Storage conditions:  
Stable and stored in an air tight container preferably in cool, dry place.  
Safety:  
  Used as pharmaceutical ingredient and is considered as nontoxic for oral formulations.
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4.0 METHODOLOGY 
CCS    : Croscarmellose Sodium  
SSG    : Sodium Starch Glycollate  
CP    : Crospovidone  
GIT    : Gastro Intestinal Tract  
hr   : Hour 
mg   : Milligram  
mm    : Milli meter  
nm    : Nano meter  
min    : Minute  
mI    : Millitre 
cm    : Centimeter 
N    : Normality  
mA    : Milli ampere  
kv    : Kilo volts  
RPM    : Revolution per minute  
s    : Second  
USP    : United State of Pharmacopoeia  
UV    : Ultraviolet  
wt    : weight  
w/w    : Weight by weight  
w/v    : Weight by volume  
v/v    : Volume by volume  
mcg    : Microgram  
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%    : Percentage  
Lit    : Litre  
Vol    : Volume  °C   : Degree Centigrade  
FDTS   : Fast Disintegrating Tablets 
FDA    : Food and Drug Administration  
F    : Formulation  
FTIR    : Formulation  
SEM    : Scanning Electron Microscopy  
SD    : Standard Deviation  
Qty    : Quantity  
µ   : Micron  
µm    : Micro meter  
µg   : Micro gram  
µg/ml    : Microgram per milliliter  
Kg/cm 2  : Kilogram per centimeter Square  
amu    : Atomic mass unit 
M/z    : Mass to charge ratio  
cm -1   : Reciprocal centimeter of wave number  
µl    : Micro litre  
    : Theta  
    : Infinity  
    : Alpha  
    : Sigma  
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    : Lamda  
    : Beta  
    : Less – than or equal to  
    : Greater – than or equal tp  
B.wt    : Body Weight  
COA    : Certificate of Analysis  
Conc    : Concentration  
G    : Gram  
ID    : identification  
V    : Volt  
µA    : Micro Ampere  
LC –MS/MS   : Liquid Chromatography – Mass Spectroscopy / Mass  
     Spectroscopy  
BLQ    : Below Limit of Quantification 
ISTD    :  Internal Standard  
QC    :  Quality Control 
CC    : Calibration Curve  
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5.0 FORMULATION OF ZOLMITRIPTAN SUBLINGUAL TABLETS 
5.1 EXPERIMENTAL METHODS 
5.1.1 Preparation of calibration curve of zolmitriptan in 0.1N hydrochloric acid  
   10mg of  zolmitriptan was dissolved in 0.1N hydrochloric acid and  volume was made 
up to 10ml in volumetric flask (1000 µg/ml). From this 1ml was diluted to 10ml to get the 
stock solution containing 100 µg/ml concentrations. 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 and 0.8ml 
of this solution was more diluted to 10ml with 0.1N hydrochloric acid to get 1 µg/ml, 2 µg/ml, 
3 µg/ml, 4 µg/ml, 5 µg/ml, 6 µg/ml, 7 µg/ml and 8 µg/ml concentration of zolmitriptan. The 
absorbance had been measured at 223 nm on a UV-VIS spectrophotomer (Schimadzu UV-
1601) against 0.1N HCl as blank. A graph of concentration versus absorbance was plotted 
(Figure-2.1). 
5.1.2 Calibration curve of zolmitriptan in mixture of buffer (pH4.0) and acetonitrile 
(90:10)  
5.1.2.1 Standard and sample zolmitriptan drug solutions preparation 
  Accurately weighed about 50mg of zolmitriptan standard and transferred into a 50ml 
standard flask, dissolved and made to the mark with the same mobile phase (mix buffer 
(pH4.0) and acetonitrile (90:10)). From this, take 5ml of the solution into 50ml standard flask 
and make up the volume. The sample solution was set by taking NLT 20 tablets containing 
each 5mg of zolmitriptan. Approximately 20 tablets were taken and powdered in a mortar. 
The powder quantity equivalent to 50mg of zolmitriptan was weighed and transferred to the 
50ml volumetric flask, dissolved this in mobile phase and diluted up to the mark with the 
same. From this take 5ml of the above solution into the 50ml standard flask and the volume 
was made with the same mobile phase. 
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5.1.2.2 λ max determination of zolmitriptan 
  Standard dilution of 100 µg/ml solution was scanned between 200nm-400nm using 
UV-VIS spectrophotomer (Schimadzu UV-1601). Based on the maximum absorption of the 
drug, the Ȝ max was found to be at 210nm. 
5.1.2.3 Preparation of mobile phase 
  Mixture of buffer (pH4.0) and acetonitrile in the ratio 90:10 
5.1.2.4 Preparation of Buffer 
   6.80gms of potassium dihydrogen orthophosphate (KH2PO4) was taken into a 2000 
ml beaker containing 1000ml of Milli –Q water. The buffer dissolved and the pH of the 
solution was adjusted by using orthophosphoric acid. After adjusting the pH (4.0), the solution 
was filtered through 0.45µm membrane filter and degassed in the sonicator. 
5.1.2.5 Calibration curve of zolmitriptan 
   Standard solutions of zolmitriptan were prepared in concentrations between 25µg/ml 
and 150µg/ml. 50mg of zolmitriptan was dissolved in mobile phase and volume was made to 
50ml with the same mobile phase (1000ȝg/ml). From this 2.5ml, 5ml, 10ml, 12.5ml and 15ml 
of the stock solution was taken and further diluted to 100ml to get 25, 50, 100, 125 and 
150µg/ml. 
  A 10µl of the drug solution was injected at a flow rate of 1.0ml/min into the column. 
The detection wavelength was monitored at 210nm wave length. The temperature of column 
was kept at 30⁰C. Each solution was injected for six times and corresponding chromatograms 
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was obtained. The graph was plotted between concentrations in µg/ml versus peak area 
(Figure-2.3). 
5.2 PREPARATION OF SUBLINGUAL TABLETS USING DIRECT 
COMPRESSION TECHNIQUE  
   In present study direct compression technique was used for the preparation of fast 
disintegrating sublingual tablets of zolmitriptan using superdisintegrants like sodium starch 
glycollate, croscarmellose sodium and crospovidone (Shangraw et al., 1989; Andries et al., 
2003). The excipients such as mannitol (100mg) and avicel pH102 (microcrystalline 
cellulose) (23% to 27%) were selected as diluents. Aspartame (0.5%) was used as sweetening 
agent and magnesium stearate (1.0%) was selected as lubricant in this study Gohel et al., 
2005; Anupama et al., 2009).. 
   Based on preparations availability in market, tablet weight was fixed. The excipients 
details were collected from USFDA recommended guidelines. Based on the disintegration 
time, various concentrations of super disintegrating agents were used. Most widely used 
superdisintegrants like sodium starch glycollate, croscarmellose sodium and crospovidone 
were used and their concentrations were optimised to get better wetting and disintegration 
time of tablets (Debord et al., 1987). 
   Prepared sublingual tablets using method of direct compression. Accurately weighed 
5mg of zolmitriptan. After passing through sieve  number  60  (Standard  test  sieves)  all  
excipients  were homogenously mixed using geometric dilution. Finally magnesium Stearate 
(Rameshwari et al., 2009; Keny et al., 2010) was added for lubrication and triturated well. 
Total nine formulations were prepared. In all the formulations, the superdisintegrant 
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concentration was varied between 2-6%. In first three formulations sodium starch glycollate 
concentrations were as 2%, 4% and 6%, the second three formulations had croscarmellose 
sodium as 2%, 4% and 6% and the last three formulations had crospovidone as 2%, 4% and 
6%. Different concentrations  of  excipients  were  used  to  prepare  various formulations of 
sublingual tablets (Al-Ghananeem et al., 2007). The blended material was compressed on 
8mm standard concave punch using a minipress (RIMEK, India) tablet punching machine.  
The total weight of tablet was made up to 150 mg (table-2.1). 
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Table-1: Composition of zolmitriptan formulations. 
 
Ingredients(mg) F1 F2 F3 F4 F5 F6 F7 F 
Zolmitriptan 5 5 5 5 5 5 5 5 
         
Sodium starch 
glycollate 3 6 9 - - - - - 
         
Croscarmellose 
sodium - - - 3 6 9 - - 
         
Crospovidone - - - - - - 3 6 
         
Avicel 102 39.75 36.75 33.75 39.75 36.75 33.75 39.75 3 
         
Aspartame 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0 
Mannitol 100 100 100 100 100 100 100 1 
Magnesium 
Stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1 
Total Weight 
(mg) 150 150 150 150 150 150 150 1 
 
Each tablet contains 5mg of zolmitriptan. 
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6.0 EVALUATION OF ZOLMITRIPTAN SUBLINGUAL TABLETS 
6.1 Evaluation of Blends 
  The flow properties of the powder were very important in handling and processing 
operations. Hence the following Micromeritic properties were studied on the zolmitriptan 
powder formulations. 
6.1.1 Angle of repose (θ) 
It is described as the maximum possible angle among the surface piles of powder to the 
horizontal plane (Lachmann et al., 1998). 
    h Tan (θ) =---------  r   
    θ  = tan-1(h/r) 
Where θ - repose angle h-is height in cm  r –is radius in cm 
  The angle of repose was measured by means of conventional fixed funnel process. 100 
gm of the drug powder had flown through the funnel which was fixed to the stand at a fixed 
height (h). Then the radius and height of the powder bed was measured. 
6.1.2 Bulk density (Db) 
This is defined as the ratio of mass of the powder to the volume of powder bulk. It 
was determined by placing 100 gm of powder material into the measuring cylinder and noted 
the initial volume of the powder. This is called as a bulk volume. Through this bulk volume, 
bulk density was calculated by using the following formula. 
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M 
Db= -------- 
Vb 
  Where M is powder mass. 
  Vb is powder bulk volume. 
  Db is bulk density. 
6.1.3 Tapped density (Dt) 
It is defined as the ratio of total powder mass to the tapped volume of powder. This 
was determined by tapping the 100 gm of powder for 750 times and noted the volume using 
tap density tester USP (Tap density Tester, Electro lab ETD-1020). The tapping is further 
continued till the differences between two successive volumes is <2% and is expressed in 
gm/ml, given by 
M 
Dt= ______ 
Vt 
 
Where M is powder mass. Vt is powder tapped volume. 
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Table-2 Powder flow properties and angle of repose 
 
Flow Property Angle of repose Compressibility Hausner’s 
 (degrees) Index (%) Ratio 
    
Excellent 25-30 ≤10 1.00-1.11 
    
Good 31-35 11-15 1.12-1.18 
    
Fair-aid not needed 36-40 16-20 1.19-1.25 
    
Passable-may hang up 41-45 21-25 1.26-1.34 
    
Poor-must agitate, vibrate 46-55 26-31 1.35-1.45 
    
Very poor 56-65 32-37 1.46-1.59 
    
Very, very poor > 66 > 38 > 1.60 
    
 
6.1.4 Carr’s Index (Compressibility percentage) 
It can be calculated from bulk and tapped density which shows powder flow 
properties and is expressed as 
         Dt-Db 
I= -------------- x 100  
Dt 
Where Dt -tapped density of the powder and Db -  bulk density of the powder 
Hausner’s Ratio 
  It is an indirect index of easy of powder flow and is calculated from the bulk and 
tapped density of zolmitriptan sublingual powder formulation, it is expressed as (Aulton et al., 
1988) 
Dt 
Hausner’s ratio = ---------- 
Db 
Where Dt is powder tapped density and Db is powder bulk density. 
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6.1.5 Determination of physical properties of tablets  
  The tablets from each formulation were subjected to the following  tests (Kumar et al., 
2010). 
6.1.6 Appearance 
The general appearance of the tablet, and overall elegance and visual identity is very 
much needed for consumer acceptance. 
6.1.7 Tablet thickness and diameter 
Thickness and diameter of tablet is very important characteristic in reproducing 
appearance. Some filling equipment utilizes the counting mechanism to get uniform thickness. 
Randomly 10 tablets were taken from each formulation and the thickness and diameter was 
determined with a vernier caliper (Mututoyo, Japan). The size of the tablet should be 
dimensionally described, monitored and controlled. 
6.1.8 Weight variation 
A group of 20 tablets were taken from each formulation randomly and weighed using 
an electronic balance (Mettler-Toledo, PB303-S/FACT, Switzerland) and the average weight 
of the tablets was determined. The individual tablet weights were compared with average 
weight. 
Table-3 Uniformity of weight 
Tablet average weight Percentage difference 
 allowed 
  
≤80 ±10 
  
Between 80 and 250 ±7.5 
  
>250 ±5 
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6.1.9 Hardness of tablets 
Strength of the tablet is defined as tensile strength (N: Newton). The crushing load on 
tablet is defined as the force necessary to fracture a tablet into 2 halves by applying 
compression (Ketan et al., 2002). The hardness of the tablet was measured by tablet hardness 
tester (Tab machines, India). 
6.1.10 Friability 
It is a measurement of mechanical strength of tablet. The friability is determined to 
evaluate the effects of rubbing and shocks which may frequently cause tablet to damage, cap 
or rupture. For this purpose Friabilator (Electro lab, India) was used (Metallic et al., 2000). A 
pre-weighed group of 20 tablets was located in the fabrilator and subjected for 100 revolutions 
(USP/NF, 2003). The dusted tablets were then reweighed. Compressed tablets must not drop 
more than 1% of their weight. 
The friability (F) is expressed by 
                                              W initial-W final 
F= -------------------------- x 100 
initial  
6.1.11 Wetting time  
Wetting time related with contact angle which is significant parameter required for fast 
dissolving tablets. The tablets with lesser wetting time have faster disintegration. The tablet 
wetting time was performed using simple procedure and it was done by placing the tablet on 
tissue paper which was located in a Petri-dish of 6.5 cm in diametercontaining 10ml of water 
at room temperature. The complete wetting time of the tablet was recorded (Honey et al., 
2008). 
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6.1.12 Disintegration time in vitro 
The tablets disintegration time was one of the important factors which are supposed to 
be optimized in development of the sublingual tablets. This test is carried out as per US FDA 
recommended guidelines for disintegration of zolmitriptan orally disintegrating tablets. This 
was tested on six tablets using Disintegration tester USP (Electro lab, ED-2AL, India), in 
distilled water at 37⁰C ±2⁰C (USP/NF, 2003). The complete disintegration of tablets without 
leaving palpable mass on the surface of mesh screen of basket assembly was noted. 
6.1.13 Water absorption ratio 
6ml of water was located in a Petri-dish and above this water a small tissue paper bend 
twice was located. The previously weighed tablet was placed gently on it and time taken for 
total wetting was noted. The weight of wetted tablet was noted. 
                            Wa-Wb 
Water absorption ratio (R) =----------------------- x 100 
                            Wb 
Here Wa and Wb are weight of tablet after and before absorption of water 
6.1.14 Dissolution in vitro 
For all the formulations the In vitro dissolution were studied (Andries et al., 2003); 
with the help of a USP dissolution test apparatus type II i.e., Paddle method (Lab India, DS 
14000, India) at a rotating speed of 50 rpm according to US FDA guidelines (Toshihiro et al., 
2003). Freshly prepared 0.1N hydrochloric acid of 500ml was placed in dissolution vessels of 
dissolution apparatus (USP, apparatus II paddle method).The tablets were placed in a 
dissolution media at 37±0.5⁰C temperature and the paddles were rotated at a speed of 50 
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RPM. 10ml of sample were collected and filtered using a 0.45µm pore size PVDF filter. The 
sample volume was immediately replaced in vessels with same volume of fresh 0.1N 
hydrochloric acid. The samples were collected at fixed times like 5min, 10min, 15min, 20min, 
30min, 45min and 60 min, diluted and analysed for drug substance with a UV-Visible 
spectrometer (Schimadzu, model UV1601, Japan) set at 223nm. The amount of the drug 
release from the tablets at definite intervals was calculated by using standard graph of 
zolmitriptan. 
6.1.15 Uniformity of content 
20 tablets were arbitrarily selected and weighed and the average weight was calculated. 
The tablets were then powdered in a glass mortar. Drug content uniformity (USP/NF, 2003) 
was measured by dissolving and diluting the crushed tablets powder in mobile phase (90:10 
%( v/v)) mix buffer (pH 4.0) and acetonitrile) and filtered through 0.45 µm membrane filter 
which was degassed. It was made necessary dilutions and analysed by using High 
Performance Liquid Chromatography (HPLC-Agilent 1100 series, USA) at the wavelength of 
210nm. The liquid chromatography equipped with UV detector and column YMC-pack ODS-
AQ (150x4.6mm, 5µm) was used. Isocratic elution was down at a flow rate 1 ml per min. The 
volume of injection was 10µl and the temperature of the column was 30⁰C. 
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6.1.16 Characterisation of zolmitriptan sublingual tablets 
6.1.17 Scanning Electron Microscopy (SEM) studies 
The surface characteristics of the zolmitriptan sublingual tablets and standard 
zolmitriptan were studied using Scanning Electron Microscope (SEM) (Scanning Electron 
Microscopy, JEOL 5400, Japan). The samples were attached on a brass stub by using a 
twofold sided adhesive tape (Rahul et al., 2009) and it was made electrically conductive by 
coating it 5-6 times and formed a layer of gold on it. Then SEM images were measured at an 
acceleration voltage of 5 kv. 
6.1.18 STABILITY STUDIES 
Optimized formulations (F9) were tested for stability studies by placing the tablets in 
the stability chamber (Thermo lab, USA) at 40±2⁰C/75±5% RH up to 3 months. The tablets 
were analyzed at a time interval of 30 days for drug content, hardness, friability, wetting time 
and in vitro disintegration time. 
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7.0 RESULTS AND DISCUSSION 
7.1 Calibration curves of zolmitriptan 
7.1.1 Calibration curve of zolmitriptan in 0.1NHCl 
       Zolmitriptan has maximum absorbance at 223nm.The calibration curve of zolmitriptan 
in 0.1N HCl was plotted by taking concentration range from 1µg/ml to 8µg/ml. The 
calibration curve for zolmitriptan in 0.1N hydrochloric acid was linear from 1-8 µg/ml with 
R2>0.99 (Figure-2.1). 
Table-4 Calibration curve of zolmitriptan in 0.1N HCl 
Concentration(µg/ml) 1 2 3 4 5 6 7 8 
         
Absorbance 0.13 0.264 0.385 0.495 0.64 0.758 0.877 0.979 
         
 
Figure- 1 Calibration curve of zolmitriptan in 0.1N HCl 
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7.1.2 Calibration curve of zolmitriptan in mixture of buffer (pH 4.0)  and acetonitrile 
(90:10) 
  The mobile phase has a mixture of buffer and acetronitrile in the ratio of 90:10 which 
showed a symmetric peak at 9.13 min. The chromatogram was shown in the figure -2.2. 
 
Figure-2 Typical chromatogram of zolmitriptan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  A calibration curve was plotted with concentration against peak area as shown in the 
figure-2.2. The linear regression showed good linearity at a concentration range (n=6) of 25-
150µg/ml and the R2 of > 0.99 was obtained. 
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Table-5 Calibration curve of zolmitriptan in mixture of buffer and acetronitril e (90%:10%) 
 
Table :5 
Conce ntration(µg/ml) Area 
  
25 663 
  
50 1298 
  
100 2602 
  
125 3275 
  
150 3952 
  
 
 
Figure-3 Calibration curve of zolmitriptan in mixture of buffer and acetronitrile 
(90%:10%) 
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Table-6 Zolmitriptan method validation parameters 
 
Parameter Value 
  
Retention time(min) 9.15 
  
Linearity 25-150µg/ml 
  
Correlation coefficient(r2) 0.999 
  
LOD 0.28 µg/ml 
  
LOQ 0.84 µg/ml 
  
Precision intra-day(%RSD) 0.87 
  
Precision inter-day(%RSD) 0.93 
  
Number of theoretical plates 5200 
  
Tailing factor 1.5 
  
Recovery 98%-103% 
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7.1.3 Evaluation of Zolmitriptan Sublingual Tablets 
Evaluation of blend 
The Micromeritic properties of the zolmitriptan powder formulations are essential in 
handling operations because the uniformity of the dose and ease of filling the powder into the 
container is determined by its flow properties. The powder flow properties can be accessed from 
Carr’s index, Hausner’s ratio and Angle of repose. Results for powder formulations were 
represented in Table-2.7. Results indicate angle of repose <33⁰ assuring that the flow properties 
were good for all formulations. Apart from this, Carr’s index and Hausner’s ratio were <14 and 
1.17 respectively for all nine formulations and showed good mixing, flow ability and 
compressibility. 
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Table-7: Powder flow properties of the zolmitriptan formulations 
 
Code Angle of Bulk Tapped Compressibility Hausner's 
1.  repose(θ) density density Index (I) Ratio 
  (gm/cm3) (gm/cm3)   
      
F1 32.4±0.1 0.23±0.01 0.26±0.01 11.39±0.25 1.15±0.03 
      
F2 32.00±0.11 0.31±0.01 0.35±0.01 11.54±0.19 1.13±0.00 
      
F3 31.6±0.18 0.22±0.01 0.25±0.01 12.01±0.48 1.13±0.01 
      
F4 31.1±0.17 0.25±0.01 0.29±0.01 13.64±0.27 1.16±0.01 
      
F5 31.3±0.04 0.25±0.01 0.28±0.01 10.86±0.61 1.12±0.00 
      
F6 30.4±0.13 0.25±0.00 0.28±0.01 11.74±1.78 1.13±0.02 
      
F7 30.0±0.13 0.27±0.01 0.30±0.01 10.11±0.20 1.11±0.01 
      
F8 30.4±0.13 0.25±0.00 0.28±0.01 10.84±0.23 1.11±0.02 
      
F9 29.8±0.14 0.26±0.01 0.29±0.01 10.46±0.21 1.12±0.00 
      
All values indicate mean ± standard deviation (SD) n=3 
7.1.3.1 Evaluation of prepared zolmitriptan sublingual tablets 
  The prepared tablets from each formulation are off white, circular, biconcave, odourless 
which were analysed for thickness, diameter, weight variation, hardness, friability, wetting 
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time, disintegration time in vitro, disintegration time in vivo, water absorption ratio, dissolution 
in vitro and uniformity of content (tables-2.8, table-2.9,table-2.10 and table-2.11). The diameter 
and thickness of all the formulations ranged from 8.03± 0.06 mm to 8.17±0.06 mm and from 
3.1±0.0 mm to 3.2±0.0 mm respectively. The average weight of the tablet in all formulations 
ranged from 150.07 ± 0.06mg to 151.37 ± 0.23 mg. All the tablets formulated in this study met 
the USP needs for weight variation (USP 31) (Ziya et al., 2011) and in all the formulations it 
was <2%. The hardness of the tablets was ranged from 4-5kg/cm2 which indicate good 
mechanical strength during compression. The friability for all the formulations showed less 
than 0.5%, demonstrating the friability was within the acceptable limits (USP 31); tablets are 
not brittle and can handle without difficulty. 
  The wetting time was measured for all the prepared formulations which were very 
important parameter in fast disintegrating tablets. It was established to be 66.0±1.0s to 
5.0±1.0s which show the highly permeable nature of the tablets. For the optimized 
formulation (F9) it was found to be 5.0±1.0s which indicates faster disintegration of the 
tablets. The percentage water absorption for all the formulations was between 
154.32±0.01% and 90.75±0.01%. 
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Table-8 Evaluation tests of sublingual tablets of zolmitriptan 
 
Formulations Diameter(mm) Thickness(mm)*** Average Hardness 
Code **  weight(mg)*** (Kg/cm2)** 
     
F1 8.03±0.06 3.17±0.06 151.3 ±0.04 4.33±0.58 
     
F2 8.07±0.06 3.13±0.06 151.37±0.23 4.33±0.58 
     
F3 8.13±0.06 3.17±0.06 151.33±0.58 4.33±0.58 
     
F4 8.13±0.06 3.10±0.06 151.23±0.12 4.66±0.58 
     
F5 8.13±0.06 3.20±0.00 151.13±0.12 4.33±0.29 
     
F6 8.17±0.06 3.17±0.06 151.5±0.10 4.16±0.29 
     
F7 8.13±0.06 3.20±0.00 150.07±0.06 4.16±0.29 
     
F8 8.10±0.00 3.10±0.00 151.17±0.06 4.5±0.50 
     
F9 8.17±0.06 3.17±0.06 151.03±0.06 4.33±0.29 
     
*** All values show mean ± standard deviation (SD) n=20  
*** All values show mean ± standard deviation (SD) n=6 Table-2.9  
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Evaluation tests of sublingual tablets of zolmitriptan  
Table : 9 
 
Formulations Friability Wetting Water 
code (%) *** Time(seconds) Absorption 
  * Ratio (%) * 
    
F1 0.28±0.02 66±1 154.32±0.01 
    
F2 0.18±0.01 55.67±0.58 147.22±0.01 
    
F3 0.13±0.01 43.67±0.58 141.06±0.00 
    
F4 0.24±0.01 15.3±0.58 129.06±0.00 
    
F5 0.30±0.01 14.3±0.58 121.32±0.00 
    
F6 0.33±0.01 12.3±0.58 117.68±0.00 
    
F7 0.29±0.01 10.67±0.58 109.45±0.00 
    
F8 0.33±0.01 6.67±0.58 106.18±0.01 
    
F9 0.30±0.02 5±1 90.75±0.01 
    
*** All values indicate mean ± standard deviation (SD) n=20 
* All values show mean ± standard deviation (SD) n=3 
The tablets in vitro disintegration time is an important parameter which is supposed to be 
optimized for the improvement of sublingual tablets. The tablet disintegration was effected by 
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the wicking, swelling nature of the disintegrant (Jinichi et al., 2006). The crospovidone 
containing tablets speedily wicks the saliva into the tablet which generates an increase in the 
volume and the hydrostatic pressure provides rapid disintegration in the mouth (Rudnic et al., 
1980). Mainly the crospovidone as superdisintegrant uses a blend of swelling and wicking 
principle. This wicking of liquid into the tablet and particles generated rapid disintegration. 
Crospovidone swells rapidly in water without getting gel formation due to its high cross link 
density (Mohanchandran et al., 2011). 
All the tablets from each formulation were disintegrated in the range varied from 
84.3±0.58s to 7.7±0.58s. From the results formulations containing crospovidone had shown less 
disintegration time as compared to various superdisintegrants. The reason for delayed 
disintegration time of sodium starch glycollate and croscarmellose sodium might be due to their 
tendency to get gel form more when compared with crospovidone. The crospovidone, 
croscarmellose sodium and sodium starch glycollate were optimized at 6% concentration. After 
these concentrations of superdisintegrants, there was no much change in the disintegration time. 
  All the formulations were checked for content uniformity. The uniformity of drug results 
was good amid various batches of tablets and the % of drug content was greater than 97.5%. The 
results also indicated acceptable and uniform dispersion of drug in all tablets (table-2.10). 
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Table-10 Evaluation tests of sublingual tablets of zolmitriptan 
Formulations code In vitro Content 
 disintegration uniformity 
 time (%) *** 
 ( seconds)**  
   
F1 84.3 ±0.58 98.06±0.89 
   
F2 57.7±0.58 98.76±1.30 
   
F3 53.7±0.58 99.09±0.19 
   
F4 16.0±1.0 102.9±0.62 
   
F5 15.67±0.58 103.31±0.56 
   
F6 15.0±1 97.66±0.41 
   
F7 11.3±0.58 101.82±0.33 
   
F8 9.3±0.58 101.23±0.41 
   
F9 7.7±0.58 102.23±0.42 
   
*** All values show mean ± standard deviation (SD) n=20  
** All  values  show  mean  ±  standard  deviation  (SD)  n=6  
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Table-11 In vitro release profile of the zolmitriptan formulations   
          
Mins/Formulation 
code** F1 F2  F3 F4 F5 F6 F7 
          
 71.16 78.83 ± 83.52 ± 77.72± 81.04± 84.13± 79.15± 
5          
 ± 2.93 2.52  1.01  0.73 0.81 0.46 0.78 
          
 78.17± 83.29 ± 93.75±  84.93± 84.87± 95.17± 86.95± 
10          
 3.60 3.70  1.74  0.80 0.54 0.90 0.49 
          
 85.15 93.32 ± 97.37 ± 91.92± 88.70± 96.08± 97.28± 
15          
 ± 2.49 3.04  0.69  0.82 0.27 0.54 0.59 
          
 91.90 98.67 ± 97.60±  97.25± 95.42± 98.38± 97.05± 
20          
 ± 1.62 0.64  0.20  0.81 0.75 0.29 0.95 
          
 97.47 101.71 ± 99.41±  99.13± 99.74± 99.52± 101.64± 
30          
 ± 1.25 1.41  0.64  0.72 0.92 0.66 0.99 
          
 98.68 103.10 ± 102.81 ± 99.13± 99.74± 100.91± 102.09± 
45          
 ± 2.56 0.40  0.80  0.72 0.92 0.62 0.69 
          
 102.62 103.57 ± 103.50 ± 101.21± 102.35± 102.97± 103.01± 
60          
 ± 1.75 0.68  0.12  0.85 0.87 0.08 0.77 
          
 
**All values indicate mean ± standard deviation (SD) n=6 
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7.1.3.2 Comparison of dissolution profile for F1, F2 and F3 zolmitriptan formulations 
containing 2%, 4% and 6% of sodium starch glycollate. 
The in vitro dissolution study of formulations F1, F2 and F3 batches showed percentage 
drug release 85.15 ± 2.49, 93.32 ± 3.04, 97.37 ± 0.69 respectively within 15 minutes. The F3 
batch showed good dissolution (figure-2.4) which contained 6% of sodium starch glycollate 
(table-2.11). 
Figure-4 Comparison of dissolution of F1, F2 and F3 zolmitriptan formulations containing 
2%, 4% and 6% of sodium starch glycollate. 
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7.1.3.3 Comparison of dissolution of F4, F5 and F6 zolmitriptan formulations containin2%, 
4% and 6% of croscarmellose Sodium. 
  The in vitro dissolution study of formulations F4, F5 and F6 batches showed percentage 
drug release 91.92±0.82, 88.70±0.27 and 96.08±0.54 respectively within 15 minutes. The F6 
batch showed good dissolution (figure-2.5) which contained 6% of croscarmellose sodium 
(table-2.11). 
Figure-5 Comparison of dissolution of F4, F5 and F6 zolmitriptan  formulations containing 
2%, 4% and 6% of croscarmellos sodium. 
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7.1.3.4 Comparison of dissolution of F7, F8and F9 zolmitriptan formulations containing 
2%, 4% and 6% of Crospovidone. 
  The in-vitro dissolution study of formulations F7, F8 and F9 showed percentage drug 
release 97.28±0.59, 97.21±0.40 and100.34±1.19 respectively within 15 minutes. The F9 batch 
showed good dissolution efficiency (100.34±1.19) and less disintegration time compared with all 
formulations (figure-2.6) which contains 6% of crospovidone (table-2.11). This formulation (F9) 
was selected as optimised and subjected for characterisation. 
Figure-6 Comparison of dissolution of F7, F8 and F9 zolmitriptan formulations containing 
2%, 4% and 6% of crospovidone. 
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7.1.4. Scanning Electron Microscopy (SEM) studies 
Surface morphology of sublingual zolmitriptan formulation and Standard zolmitriptan 
were examined by scanning electron microscopy (Figure-2.7). The SEM micrographs reveal that 
there is no segregation or deposition of particles on the surface of sublingual tablets (Alhusban et 
al., 2010). 
Figure-7 Scanning Electron Microscope images of a) zolmitriptan standard b) 
zolmitriptan sublingual tablets. 
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7.1.5. Evaluation of stability studies  
  The optimized form ulation (F9) were subjected for stability studies by  keeping the 
formulation a t 40±2⁰ C/75±5% RH and analyzed for every month for three months. Drug 
content, hardness, friability, wetti ng time and disintegration time in vitro were evaluated. The 
optimized for mulations are stable and did not show much variation in any of the paramet ers 
(Sunita et al., 2010). 
Table-12 Effect of storage of formulation F9 at 40±2⁰ C/75±5% RH 
 
Code/day Drug Hardness Friability Wetting In vitro  
F9 content (%) (kg/cm2) (%) *** time (min) disintegration  
 ** **  * (min) **  
       
1St day 102.23±0.42 4.33±0.29 0.30±0.02 5.00±1.00 
7.7±0.58 
 
      
       
30Th day 101.91±0.01 4.33±0.58 0.30±0.01 5.33±0.58 7.67±0.58  
       
60Th day 101.9±0.01 4.16±0.29 0.33±0.01 5.33±0.58 8.0±0.0  
       
90Th day 101.87±0.01 4.66±0.58 0.33±0.01 5.33±0.586 8.0±0.0  
       
 
*** All values show mean ± standard deviation (SD) n=20  
** All values show mean ± standard deviation (SD) n=6  
*  All values show mean ± standard deviation (SD) n=3  
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8.0 CONCLUSION 
 
Fast dissolving zolmitriptan  sublingual tablet was prepared with the help of direct 
compression technique by using sodium starch glycollate, croscarmellose sodium and 
crospovidone as superdisintegrants. The formulae was optimized for zolmitriptan  sublingual 
tablet to give fast relief and increase the patient compliance. The unpleasant taste of these drug 
was masked by aspartame (sweetener). The tablet containing 6% of crospovidone showed faster 
disintegration and more dissolution efficiency. The characterisation of optimised formulation 
was done and the result showed without any interaction among the drug and excipients. 
Optimized formulation was subjected to stability studies and studies confirmed that the tablet 
was stable. These optimised formulation was evaluated for in vivo release studies using rabbit 
model and showed effective therapeutic Cmax when compared to clinical dose. The study 
concludes that these formulated fast disintegrating sublingual tablet is promising alternative to 
oral administration route in acute management of migraine. 
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9.0 SUMMARY 
  In the present study fast disintegrating sublingual tablets of potent anti-migraine drug of 
zolmitriptan (5mg/tablet) and was prepared by the help of direct compression technique. The 
superdisintegrants used were sodium starch glycollate, croscarmellose sodium and crospovidone. 
Mannitol and avicel pH102 (microcrystalline cellulose) were used as diluents. Aspartame was 
used as a sweetener and magnesium stearate was selected as a lubricant. 
  The blend of all powder formulation was examined for angle of repose, Carr’s 
Compressibility Index and Hausner’s Ratio. Results showed that the angle of repose is <33⁰ 
assuming good flow properties for formulation. Carr’s compressibility index and Hausner’s ratio 
were found to be <14 and <1.17 for zolmitriptan powder formulation respectively, ensuring that 
all the preparation resulted in good mixing, flow ability and compressible characteristics. The 
formulated tablet was evaluated for physiochemical properties and dissolution efficiency. Good 
drug uniformity results were established among different batches of tablet and it was more than 
97.5% (p<0.05) in zolmitriptan. 
The wetting time and disintegration time for zolmitriptan sublingual tablet was found to 
be 66.0±1.0s to 5.0±1.0s and 84.3±0.58s to 7.7±0.58s respectively. The tablet containing 6% 
crospovidone showed faster disintegration and more dissolution efficiency. The tablet 
disintegration was effected by the wicking and swelling nature of the disintegrants. The 
crospovidone present in the tablets is responsible for the quick wicks of saliva into the tablet and 
volume expansion is generated and hydrostatic pressure, which provides quick disintegration in 
the mouth (Jinichi et al., 2006). Based on faster disintegration and dissolution efficiency the 
formulation nine (F9) was selected as optimised. The wetting and disintegration time for 
SUMMARY   
                               
 
 
Padmavathi College of Pharmacy and Research Institute                                                               Page 77 of 93 
 
optimised formulation (F9) was found to be 5±1s and 7.7±0.58s for zolmitriptan tablet. The 
optimised formulation showed 100.34±1.19 dissolution efficiency for zolmitriptan sublingual 
tablet. 
The optimized formulation was characterized with the help of Scanning Electron 
Microscopy (SEM), Differential Scanning Calorimetry (DSC), Powder X-ray Diffractometry 
(PXRD) and Fourier Transform Infrared Spectroscopy (FTIR); in this formulation the SEM 
pictures reveal that there was no segregation or deposition of particles on the surface of 
sublingual tablet. From DSC and PXRD studies, it was observed that in this optimised 
formulation the drug exists in crystalline form without having polymorphic change. FTIR studies 
revealed that the drug and excipients did not have interactions. Based on disintegration and 
dissolution studies, the optimized preparations were subjected to stability studies. These 
formulation was analysed for drug content, friability, hardness, wetting time and in vitro 
disintegration time for three months. The optimised formulation was stable and did not show 
much variation in any of the parameters. 
Comparative pharmacokinetic studies of prepared zolmitriptan tablet (5mg/tablet) and 
intravenous injection (5mg/kg) were carried out using New Zealand rabbits. The Cmax, T1/2, 
Tmax and AUC were calculated. 
Peak serum concentration attained by the test item zolmitriptan was 140.622ng/ml and 
2500.846ng/ml following sublingual and intravenous administration respectively. The time 
needed to attain peak serum concentration by drug, following sublingual and intravenous 
administration was 1 hr and 0.083 hr respectively. The area under the curve AUC(0 – 24), was 
found to be 231.769 ng.hr/ml and 1712.739 ng.hr/ml for sublingual and intravenous 
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administration respectively. AUC(0 - ∞) was calculated and was found to be 295.131ng.hr/ml 
and 1750.454ng.hr/ml for sublingual and intravenous administration respectively. The T1/2 was 
found to be 0.855 hr and 1.665 hr following sublingual and intravenous administration 
respectively. 
Intra venous route gives 100% bioavailability where as oral or sublingual gives less 
bioavailability due to absorption, first-pass effect, receptor binding, rapid absorption etc. In the 
present market zolmitriptan oral and nasal formulations are available and the oral bioavailability 
of zolmitriptan is 25% (10mg/kg rabbit) suggesting significant first metabolism in rabbit. So 
sublingual route of administration helps the bioavailability and the maximum concentrations 
attained with zolmitriptan at 5mg tablet in rabbits elicits the pharmacological activity. The main 
object of this study is to show fast absorption of the drug and provide more consistent relief from 
migraine. 
In conclusion, the average plasma concentration-time profiles for zolmitriptan 5 mg tablet 
by sublingual route show quite rapid initial drug absorption, on normal reaching 80% of eventual 
Cmax within 1 hour and 5 mg/kg intravenous route show time to peak plasma concentration 
within 1 hour. Zolmitriptan 5 mg tablet by sublingual route in rabbits showed effective 
therapeutic Cmax (140.622 ng/ml) when compared to clinical dose by oral route (5.6 ng/ml). 
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